Bank Hapoalim BM’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Bank Hapoalim BM’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,925	Closed	-$504K	–	252
2021 Q4	$504K	Sell	10,925 -1,247	-10%	-$59.1K	0.05%	167
2021 Q3	$577K	Sell	12,172 -290	-2%	-$14.4K	0.06%	155
2021 Q2	$645K	Sell	12,462 -1,080	-8%	-$54.2K	0.07%	155
2021 Q1	$682K	Sell	13,542 -830	-6%	-$44.2K	0.09%	143
2020 Q4	$748K	Sell	14,372 -520	-3%	-$24.9K	0.1%	119
2020 Q3	$647K	Sell	14,892 -15,880	-52%	-$696K	0.03%	104
2020 Q2	$1.32M	Buy	30,772 +2,710	+10%	+$112K	0.31%	64
2020 Q1	$1.01M	Sell	28,062 -2,423	-8%	-$103K	0.32%	65
2019 Q4	$1.39M	Buy	30,485 +2,315	+8%	+$91.8K	0.31%	63
2019 Q3	$1.01M	Buy	28,170 +880	+3%	+$32.7K	0.25%	64
2019 Q2	$1.09M	Sell	27,290 -845	-3%	-$33.2K	0.27%	68
2019 Q1	$1.17M	Buy	28,135 +11,070	+65%	+$450K	0.28%	62
2018 Q4	$625K	Buy	17,065 +3,650	+27%	+$156K	0.2%	80
2018 Q3	$651K	Buy	13,415 +550	+4%	+$26.1K	0.16%	104
2018 Q2	$553K	Buy	12,865 +694	+6%	+$29.2K	0.15%	120
2018 Q1	$510K	Buy	12,171 +90	+0.7%	+$3.92K	0.13%	115
2017 Q4	$526K	Sell	12,081 -1,060	-8%	-$45.1K	0.12%	125
2017 Q3	$559K	Buy	13,141 +2,760	+27%	+$117K	0.13%	132
2017 Q2	$447K	Sell	10,381 -2,195	-17%	-$92.5K	0.11%	136
2017 Q1	$526K	Sell	12,576 -1,755	-12%	-$71.5K	0.12%	117
2016 Q4	$560K	Buy	14,331 +7,575	+112%	+$308K	0.15%	103
2016 Q3	$299K	Sell	6,756 -580	-8%	-$26.3K	0.07%	154
2016 Q2	$307K	Sell	7,336 -132	-2%	-$5.59K	0.07%	142
2016 Q1	$301K	Sell	7,468 -11,962	-62%	-$507K	0.07%	131
2015 Q4	$995K	Sell	19,430 -19,754	-50%	-$1.01M	0.23%	70
2015 Q3	$1.84M	Buy	39,184 +2,544	+7%	+$153K	0.43%	51
2015 Q2	$2.29M	Buy	36,640 +10,110	+38%	+$630K	0.45%	44
2015 Q1	$1.64M	Buy	+26,530	New	+$1.57M	0.3%	60

Other funds holding XPH

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

FFM

Fullerton Fund Management Singapore $1.56B AUM 88.19% 1-Year Est. Return

Bank Hapoalim BM's XPH Position: Q1 2022 in Review

Bank Hapoalim BM sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q1 2022, closing a stake of 10,925 shares — an estimated $504K sold.

Bank Hapoalim BM first reported a position in XPH in Q1 2015 and held it in 28 quarters. The position peaked at $2.29M in Q2 2015. 69 funds tracked by Wall St. Rank hold XPH as of Q1 2022.

Bank Hapoalim BM reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q1 2022 after selling out during the quarter.
Bank Hapoalim BM sold 10,925 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2022, an estimated $504K.
Bank Hapoalim BM first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2015 and held it in 28 quarters.
Bank Hapoalim BM's State Street SPDR S&P Pharmaceuticals ETF position peaked at $2.29M in Q2 2015.
69 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2022.

Based on Bank Hapoalim BM's 13F filing for Q1 2022, filed 28 Apr 2022.